Andrew Haydon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrew Haydon has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- John Raymond Zalcberg
Cancer Research Program, School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia
3 shared publications - Suzanne Gaye Orchard
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
3 shared publications - Jaidyn Muhandiramge
School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia
2 shared publications - John James McNeil
School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia
2 shared publications - Robyn Lorraine Woods
School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia
2 shared publications - Rory Wolfe
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
2 shared publications
Latest Publications
- Open Access
Cancer Treatment Patterns and Factors Affecting Receipt of Treatment in Older Adults: Results from the ASPREE Cancer Treatment Substudy (ACTS)
Introduction: Cancer treatment planning in older adults is complex and requires careful balancing of survival, quality of life benefits, and risk of treatment-related morbidity and toxicity. As a result, treatment selection in this cohort tends to differ from that for younger patients. However, there are very few studies describing cancer treatment patterns in older cohorts. Methods: We used data from the ASPirin in Reducing Events in the Elderly (ASPREE) trial and the ASPREE Cancer Treatment Substudy (ACTS) to describe cancer treatment patterns in older adults. We used a multivariate logistic regression model to identify factors affecting receipt of treatment. Results: Of 1893 eligible Australian and United States (US) participants with incident cancer, 1569 (81%) received some form of cancer treatment. Non-metastatic breast cancers most frequently received treatment (98%), while haematological malignancy received the lowest rates of treatment (60%). Factors associated with not receiving treatment were older age (OR 0.94, 95% CI 0.91–0.96), residence in the US (OR 0.34, 95% CI 0.22–0.54), smoking (OR 0.57, 95% CI 0.40–0.81), and diabetes (OR 0.56, 95% CI 0.39–0.80). After adjustment for treatment patterns in sex-specific cancers, sex did not impact receipt of treatment. Conclusions: This study is one of the first describing cancer treatment patterns and factors affecting receipt of treatment across common cancer types in older adults. We found that most older adults with cancer received some form of cancer treatment, typically surgery or systemic therapy, although this varied by factors such as cancer type, age, sex, and country of residence.
Open AccessCancer Treatment Patterns and Factors Affecting Receipt of Treatment in Older Adults: Results from the ASPREE Cancer Treatment Substudy (ACTS)
Introduction: Cancer treatment planning in older adults is complex and requires careful balancing of survival, quality of life benefits, and risk of treatment-related morbidity and toxicity. As a result, treatment selection in this cohort tends to differ from that for younger patients. However, there are very few studies describing cancer treatment patterns in older cohorts. Methods: We used data from the ASPirin in Reducing Events in the Elderly (ASPREE) trial and the ASPREE Cancer Treatment Substudy (ACTS) to describe cancer treatment patterns in older adults. We used a multivariate logistic regression model to identify factors affecting receipt of treatment. Results: Of 1893 eligible Australian and United States (US) participants with incident cancer, 1569 (81%) received some form of cancer treatment. Non-metastatic breast cancers most frequently received treatment (98%), while haematological malignancy received the lowest rates of treatment (60%). Factors associated with not receiving treatment were older age (OR 0.94, 95% CI 0.91–0.96), residence in the US (OR 0.34, 95% CI 0.22–0.54), smoking (OR 0.57, 95% CI 0.40–0.81), and diabetes (OR 0.56, 95% CI 0.39–0.80). After adjustment for treatment patterns in sex-specific cancers, sex did not impact receipt of treatment. Conclusions: This study is one of the first describing cancer treatment patterns and factors affecting receipt of treatment across common cancer types in older adults. We found that most older adults with cancer received some form of cancer treatment, typically surgery or systemic therapy, although this varied by factors such as cancer type, age, sex, and country of residence.
- Open Access
- 2 December 2022
- Published by Springer Nature in Cardio-Oncology
- Vol. 8 (1) , 1-8
Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study
Background: Immune checkpoint inhibitors (ICI) are associated with immune-mediated adverse effects, potentially involving any organ. ICI has also been associated with an increased risk of cardiovascular disease in cancer populations. Objective: To characterize the incidence and risk of major atherosclerotic cardiovascular events associated with ICI use in a high-risk and advanced melanoma population. Methods: We conducted a retrospective cohort study of patients with high-risk or advanced melanoma (AJCC stage II, III or IV) presenting to an academic tertiary hospital between 2015–2020. The main outcome was major atherosclerotic cardiovascular events (MACE) including acute myocardial infarction, ischemic stroke, acute limb ischemia and coronary revascularization. Results: The study cohort consisted of 646 patients, including 289 who had been treated with ICI. The incidence of MACE was higher in the ICI treated group (3.6 vs. 0.9 events per 100-person years). After adjusting for age, sex, smoking history and prior BRAF and/or MEK inhibitor use, ICI treatment was associated with an increased risk of MACE (HRadj 2.8, 95% CI 1.1–6.9, p = 0.03). Elevated risk was especially pronounced in patients with a past history of MACE (HR 14.4, 95% CI 1.9–112.3, p = 0.01). Conclusion: Patients with high-risk or advanced melanoma are at an increased risk of atherosclerotic cardiovascular events following ICI treatment, particularly those with a history of cardiovascular disease.
- 2 December 2022
- Published by Springer Nature in Cardio-Oncology
- Vol. 8 (1) , 1-8
Open AccessImmune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study
Background: Immune checkpoint inhibitors (ICI) are associated with immune-mediated adverse effects, potentially involving any organ. ICI has also been associated with an increased risk of cardiovascular disease in cancer populations. Objective: To characterize the incidence and risk of major atherosclerotic cardiovascular events associated with ICI use in a high-risk and advanced melanoma population. Methods: We conducted a retrospective cohort study of patients with high-risk or advanced melanoma (AJCC stage II, III or IV) presenting to an academic tertiary hospital between 2015–2020. The main outcome was major atherosclerotic cardiovascular events (MACE) including acute myocardial infarction, ischemic stroke, acute limb ischemia and coronary revascularization. Results: The study cohort consisted of 646 patients, including 289 who had been treated with ICI. The incidence of MACE was higher in the ICI treated group (3.6 vs. 0.9 events per 100-person years). After adjusting for age, sex, smoking history and prior BRAF and/or MEK inhibitor use, ICI treatment was associated with an increased risk of MACE (HRadj 2.8, 95% CI 1.1–6.9, p = 0.03). Elevated risk was especially pronounced in patients with a past history of MACE (HR 14.4, 95% CI 1.9–112.3, p = 0.01). Conclusion: Patients with high-risk or advanced melanoma are at an increased risk of atherosclerotic cardiovascular events following ICI treatment, particularly those with a history of cardiovascular disease.
- 1 April 2021
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 12 (3) , 343-351
The acceleration of ageing in older patients with cancer
- 1 April 2021
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 12 (3) , 343-351
The acceleration of ageing in older patients with cancer
- 31 July 2020
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 96, 106095
Cancer history and risk factors in healthy older people enrolling in the ASPREE clinical trial
- 31 July 2020
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 96, 106095
Cancer history and risk factors in healthy older people enrolling in the ASPREE clinical trial
- 17 January 2018
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 14 (5) , e442-e447
High neutrophil‐to‐lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy
Aim: To evaluate the role of neutrophil‐to‐lymphocyte ratio as a prognostic marker in squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy.Methods: A retrospective chart review was performed on patients presenting to our service between 2001 and 2014. Overall survival (OS) and progression‐free survival (PFS) were calculated using Kaplan–Meier estimates. The association between neutrophil‐to‐lymphocyte ratio and survival was analyzed by both univariate and multivariate analysis.Results: Across all patients, OS and PFS at 5 years was 59% and 54%, respectively. Increasing T stage correlated with a statistically significant decrease in OS (P = 0.004) and PFS (P = 0.005). Both overall (P = 0.003) and PFS (P = 0.002) were highest in lifetime nonsmokers and lowest in current smokers. Patients who commenced treatment in 2010 or later had a significantly greater overall (P = 0.014) and PFS (P = 0.009) compared to those treated prior. Patients with p16 negative tumors had a significantly lower overall (P < 0.001) and PFS (P < 0.001) compared to those with p16 positive tumors. Patients treated with cisplatin had an overall and PFS of 66.8% and 59.9% respectively at 5 years. Patients with a neutrophil‐to‐lymphocyte ratio of less than 4 at treatment initiation had a significantly greater overall (P = 0.015) and PFS (P = 0.017). The trend for OS remained significant in multivariate analysis (P = 0.05).Conclusion: A high neutrophil‐to‐lymphocyte ratio at treatment initiation is a negative predictive marker for squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy.
- 17 January 2018
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 14 (5) , e442-e447
High neutrophil‐to‐lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy
Aim: To evaluate the role of neutrophil‐to‐lymphocyte ratio as a prognostic marker in squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy.Methods: A retrospective chart review was performed on patients presenting to our service between 2001 and 2014. Overall survival (OS) and progression‐free survival (PFS) were calculated using Kaplan–Meier estimates. The association between neutrophil‐to‐lymphocyte ratio and survival was analyzed by both univariate and multivariate analysis.Results: Across all patients, OS and PFS at 5 years was 59% and 54%, respectively. Increasing T stage correlated with a statistically significant decrease in OS (P = 0.004) and PFS (P = 0.005). Both overall (P = 0.003) and PFS (P = 0.002) were highest in lifetime nonsmokers and lowest in current smokers. Patients who commenced treatment in 2010 or later had a significantly greater overall (P = 0.014) and PFS (P = 0.009) compared to those treated prior. Patients with p16 negative tumors had a significantly lower overall (P < 0.001) and PFS (P < 0.001) compared to those with p16 positive tumors. Patients treated with cisplatin had an overall and PFS of 66.8% and 59.9% respectively at 5 years. Patients with a neutrophil‐to‐lymphocyte ratio of less than 4 at treatment initiation had a significantly greater overall (P = 0.015) and PFS (P = 0.017). The trend for OS remained significant in multivariate analysis (P = 0.05).Conclusion: A high neutrophil‐to‐lymphocyte ratio at treatment initiation is a negative predictive marker for squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy.
- Open Access
- 10 August 2017
- Published by Springer Nature in British Journal of Cancer
- Vol. 117 (7) , 921-924
Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy
Background: Immune-mediated myocarditis is an uncommon adverse effect of immune checkpoint inhibition and is associated with a high rate of mortality. Methods: In this reported case, a 64-year-old woman with right temporo-parietal glioblastoma IDH-WT was treated with nivolumab, temozolomide and radiation therapy on a clinical trial. She developed malignant arrhythmias secondary to histologically confirmed severe immune-mediated myocarditis. She was treated with equine anti-thymocyte globulin (ATGAM) due to development of malignant arrhythmias refractory to high-dose corticosteroids. Results: This report describes the only case of immune-mediated myocarditis treated with ATGAM resulting in a favourable outcome. Conclusions: Use of ATGAM should be considered in cases of steroid-refractory immune-mediated myocarditis and administered in close consultation with a cardiac transplant team experienced in the use of this agent.
- 10 August 2017
- Published by Springer Nature in British Journal of Cancer
- Vol. 117 (7) , 921-924
Open AccessSuccessful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy
Background: Immune-mediated myocarditis is an uncommon adverse effect of immune checkpoint inhibition and is associated with a high rate of mortality. Methods: In this reported case, a 64-year-old woman with right temporo-parietal glioblastoma IDH-WT was treated with nivolumab, temozolomide and radiation therapy on a clinical trial. She developed malignant arrhythmias secondary to histologically confirmed severe immune-mediated myocarditis. She was treated with equine anti-thymocyte globulin (ATGAM) due to development of malignant arrhythmias refractory to high-dose corticosteroids. Results: This report describes the only case of immune-mediated myocarditis treated with ATGAM resulting in a favourable outcome. Conclusions: Use of ATGAM should be considered in cases of steroid-refractory immune-mediated myocarditis and administered in close consultation with a cardiac transplant team experienced in the use of this agent.